Kura Oncology annual debt-to-assets ratio
2014
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Kura Oncology Debt-to-Assets Ratio Growth & History (KURA)
Kura Oncology's debt-to-assets ratio was 0.03 for fiscal 2025.
View full Kura Oncology company overviewKura Oncology annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.03 | 0.01 | +26.92% |
| 2024 | 2024-12-31 | 0.02 | −0.02 | −43.02% |
| 2023 | 2023-12-31 | 0.04 | 0.01 | +24.66% |
| 2022 | 2022-12-31 | 0.03 | 0.02 | +138.74% |
| 2021 | 2021-12-31 | 0.01 | −0.01 | −44.27% |
| 2020 | 2020-12-31 | 0.02 | −0.01 | −28.34% |
| 2019 | 2019-12-31 | 0.03 | −0.01 | −21.61% |
| 2018 | 2018-12-31 | 0.04 | −0.03 | −44.47% |
| 2017 | 2017-12-31 | 0.07 | −0.03 | −29.40% |
| 2016 | 2016-12-31 | 0.10 | — | — |
| 2014 | 2014-12-31 | 1.48 | — | — |
Kura Oncology quarterly debt-to-assets ratio
Q4.14
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.04 | 0.01 | +45.80% |
| Q1 2026 | 2026-03-31 | 0.04 | 0.01 | +42.95% |
| Q4 2025 | 2025-12-31 | 0.03 | 0.01 | +26.92% |
| Q3 2025 | 2025-09-30 | 0.03 | −0.00 | −13.68% |
| Q2 2025 | 2025-06-30 | 0.03 | −0.00 | −12.16% |
| Q1 2025 | 2025-03-31 | 0.03 | −0.00 | −15.06% |
| Q4 2024 | 2024-12-31 | 0.02 | −0.02 | −43.02% |
| Q3 2024 | 2024-09-30 | 0.03 | −0.00 | −5.57% |
| Q2 2024 | 2024-06-30 | 0.03 | 0.01 | +23.21% |
| Q1 2024 | 2024-03-31 | 0.03 | −0.00 | −3.61% |
| Q4 2023 | 2023-12-31 | 0.04 | 0.01 | +24.66% |
| Q3 2023 | 2023-09-30 | 0.04 | 0.02 | +206.01% |
| Q2 2023 | 2023-06-30 | 0.03 | 0.01 | +110.95% |
| Q1 2023 | 2023-03-31 | 0.03 | 0.02 | +148.01% |
| Q4 2022 | 2022-12-31 | 0.03 | 0.02 | +138.74% |
| Q3 2022 | 2022-09-30 | 0.01 | −0.00 | −8.28% |
| Q2 2022 | 2022-06-30 | 0.01 | 0.00 | +8.52% |
| Q1 2022 | 2022-03-31 | 0.01 | −0.01 | −42.39% |
| Q4 2021 | 2021-12-31 | 0.01 | −0.01 | −44.27% |
| Q3 2021 | 2021-09-30 | 0.01 | −0.03 | −71.16% |
| Q2 2021 | 2021-06-30 | 0.01 | −0.03 | −73.36% |
| Q1 2021 | 2021-03-31 | 0.02 | −0.02 | −48.16% |
| Q4 2020 | 2020-12-31 | 0.02 | −0.01 | −28.34% |
| Q3 2020 | 2020-09-30 | 0.05 | 0.01 | +46.76% |
| Q2 2020 | 2020-06-30 | 0.04 | 0.01 | +43.72% |
| Q1 2020 | 2020-03-31 | 0.04 | −0.00 | −10.13% |
| Q4 2019 | 2019-12-31 | 0.03 | −0.01 | −21.61% |
| Q3 2019 | 2019-09-30 | 0.03 | −0.00 | −5.40% |
| Q2 2019 | 2019-06-30 | 0.03 | −0.02 | −43.99% |
| Q1 2019 | 2019-03-31 | 0.05 | −0.00 | −5.61% |
| Q4 2018 | 2018-12-31 | 0.04 | −0.03 | −44.47% |
| Q3 2018 | 2018-09-30 | 0.03 | −0.04 | −52.09% |
| Q2 2018 | 2018-06-30 | 0.05 | −0.08 | −59.21% |
| Q1 2018 | 2018-03-31 | 0.05 | −0.07 | −57.33% |
| Q4 2017 | 2017-12-31 | 0.07 | −0.03 | −29.40% |
| Q3 2017 | 2017-09-30 | 0.07 | −0.03 | −28.69% |
| Q2 2017 | 2017-06-30 | 0.13 | 0.04 | +47.64% |
| Q1 2017 | 2017-03-31 | 0.12 | — | — |
| Q4 2016 | 2016-12-31 | 0.10 | — | — |
| Q3 2016 | 2016-09-30 | 0.10 | — | — |
| Q2 2016 | 2016-06-30 | 0.09 | — | — |
| Q4 2014 | 2014-12-31 | 1.48 | — | — |
Kura Oncology debt-to-assets ratio trends
Over the last five fiscal years, Kura Oncology's debt-to-assets ratio increased from 0.02 to 0.03, a change of 0.00. The latest reported quarter, Q2 2026, shows 0.04.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kura Oncology source filings ↗